2023-05-08 15:35:50 ET
Clinical-stage biotech Immunic ( NASDAQ: IMUX ) added ~5% Monday after disclosing clinical and preclinical data for its bowel disease candidate IMU-856 in a poster presentation at a medical event.
The findings, as disclosed at the ongoing Digestive Disease Week 2023 in Chicago, IL indicate the favorable effects of IMU-856 on the protection and regeneration of the gut lining, the company said.
Additionally, IMU-856, an orally available small molecule modulator of gut protein SIRT6, was found to induce a dose-dependent effect on the tightening of the intestinal barrier. SIRT6, also known as Sirtuin 6, is believed to play a role in the intestinal barrier function and regeneration of bowel epithelium.
"By restoring intestinal barrier function and bowel wall architecture through its effect on SIRT6, IMU-856 may offer a unique treatment option for patients suffering from gastrointestinal diseases," Hella Kohlhof, Chief Scientific Officer at Immunic ( IMUX ), said.
Immunic ( IMUX ) reaffirmed its plans to start a Phase 2 trial for IMU-856 in celiac disease days after announcing proof of concept data for the candidate from a Phase 1 clinical trial last week.
More on Immunic
- Immunic surges ~20% as IMU-838 shows promise in ulcerative colitis trial
- Immunic: Multiple Sclerosis Data In H2 2023 Could Provide Major Shift
For further details see:
Immunic gains after early-stage data for bowel disease candidate